logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Tocilizumab (RoActemra) for Adults with Systemic Sclerosis – Second Line

< Back

Tocilizumab (RoActemra) for Adults with Systemic Sclerosis – Second Line

Drugs

Orthopaedics

December 2017


There is currently no cure for systemic sclerosis and treatment options focus on the management of symptoms. Tocilizumab is intended for the treatment of systemic sclerosis in adults. It is currently in development and early research indicates that it is able to target the key mechanisms thought to be responsible for the disease. If licensed, it could provide a new treatment option for adults with systemic sclerosis.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Tocilizumab for Systemic Sclerosis



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts